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Machine learning for the detection 
of early immunological markers 
as predictors of multi-organ 
dysfunction
Laura Bravo-Merodio  1,2,9, Animesh acharjee  1,2,3,9*, Jon Hazeldine3,4, Conor Bentley  3,4, 
Mark Foster3,5, Georgios V. Gkoutos  1,2,3,6,7,8* & Janet M. Lord  3,4,8
the immune response to major trauma has been analysed mainly within post-hospital admission 
settings where the inflammatory response is already underway and the early drivers of clinical outcome 
cannot be readily determined. Thus, there is a need to better understand the immediate immune 
response to injury and how this might influence important patient outcomes such as multi-organ 
dysfunction syndrome (MODS). In this study, we have assessed the immune response to trauma in 61 
patients at three different post-injury time points (ultra-early (<=1 h), 4–12 h, 48–72 h) and analysed 
relationships with the development of MODS. We developed a pipeline using Absolute Shrinkage and 
Selection Operator and Elastic Net feature selection methods that were able to identify 3 physiological 
features (decrease in neutrophil CD62L and CD63 expression and monocyte CD63 expression and 
frequency) as possible biomarkers for MODS development. After univariate and multivariate analysis 
for each feature alongside a stability analysis, the addition of these 3 markers to standard clinical 
trauma injury severity scores yields a Generalized Liner Model (GLM) with an average Area Under the 
Curve value of 0.92 ± 0.06. This performance provides an 8% improvement over the Probability of 
Survival (PS14) outcome measure and a 13% improvement over the New Injury Severity Score (NISS) for 
identifying patients at risk of MODS.
Introduction
Trauma is responsible for the deaths of 4.9 million people worldwide according to the latest World Health 
Organization (WHO) reports1, with two thirds of patients dying as a result of sequelae other than the immediate 
injury and haemorrhage2. Secondary complications such as acute respiratory distress syndrome (ARDS), noso-
comial infections, sepsis or multi-organ dysfunction syndrome (MODS) with multi organ failure (MOF) at the 
end of the spectrum, have therefore become increasingly significant, creating an urgent need to develop novel 
approaches by which to identify patients at risk. MODS, a progressive failure of several independent organ sys-
tems, occurs in 30% to 40% of trauma patients3, with nearly 50% of those in the Intensive Care Unit (ICU) dying 
as a result4.
Given its complexity, the underlying biological processes driving MODS have not yet been completely elu-
cidated, although an exacerbated and dysregulated inflammatory response that impairs the body’s own heal-
ing mechanisms has been identified as a key driver of MODS development5–7. After a severe injury tissue 
damage and ischaemia lead to the release of inflammatory mediators locally that drive a pronounced systemic 
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pro-inflammatory response (SIRS) that can promote further damage. In compensation, an anti-inflammatory 
response (CARS)8 occurs concomitantly9 and drives homeostasis restoration and tissue repair mechanisms. 
However, when exacerbated, a pronounced and extended anti-inflammatory signature can drive a state of 
immune suppression, leaving injured patients with increased susceptibility to secondary infections and sep-
sis2. Examining the balance between SIRS and CARS is therefore essential to understand possible outcomes for 
trauma patients9. For instance, a higher serum level of the pro-inflammatory cytokine interferon-γ (IFN-γ)5 and 
a raised frequency of natural killer T cells9 have been shown to be associated with MODS development9. Impaired 
bactericidal function is also seen after trauma and is associated with MODS and sepsis, possibly explained by the 
increase in immature neutrophils seen after trauma9,10. Moreover, activated platelets and neutrophil extracellular 
trap (NET) generation are also associated with organ dysfunction10.
In the Golden Hour study9, we aim to characterise the immune signature of patients during the very early 
response to trauma to better understand and predict their later development of adverse outcomes such as MODS 
and sepsis. Given the abrupt nature of a traumatic injury, knowledge of the physiological response after trauma 
has largely been based on post-admission to hospital blood samples. However recent studies9–11 have suggested 
that by then the body’s immune response might already be set towards a helpful or dysregulated response and 
subsequent positive or negative patient outcomes. Therefore, the predictive value of immune information imme-
diately after severe injury (before 2 hours) can help provide optimal care for patients, encouraging interventions 
such as early total care, damage control orthopaedic surgery (DOC) or guiding immunomodulatory therapies12,13. 
Moreover, the immediate immune signature has been shown to hold predictive information for outcomes such as 
MODS and mortality unaccounted for in later time points6.
In the previous report of our data9, relatively simple statistical analysis and modelling was performed. Here 
extended analysis with approaches stemming from the field of Artificial Intelligence (AI) and in particular 
Machine Learning (ML), have been performed. Specifically, we have addressed the inadequacies of the current 
clinical scoring systems used for the assessment of trauma severity, namely New Injury Severity Score (NISS) 
and Probability of Survival (PS14). They are the main outcome measurements evaluated in TARN (the Trauma 
Audit and Research Network) and have both shown a high correlation with mortality and length of stay and act 
as the general predictors for outcomes such as MODS development14 and sepsis, irrespective of the underlying 
biological differences of the outcomes. NISS is based on the sum of squares of the Abbreviated Injury Scale (AIS) 
scores of a patient’s injuries and hence is limited to anatomical information only, whereas PS14 is modelled based 
on age, gender, Injury Severity Score (ISS), pre-existing medical conditions, patient outcome (up to 30 days)15 and 
Glasgow Coma Score (GCS)16.
Our approach attempts to incorporate immunological information in order to improve our ability to objec-
tively assess a patient’s risk of MODS. Previous studies have shown the predictive ability of particular inflam-
matory effectors such as cell free DNA (cfDNA), mitochondrial DNA (mtDNA) or high mobility box 1 protein 
(HMGB1)17,18, present as a result of cell debris and necrosis associated with traumatic injuries. We believe that, 
based on the novelty of the study, outcomes resulting from the analysis of such early events after trauma, are of 
the utmost importance, and can assist in the development of new strategies to better stratify and treat patients.
Some recent examples of machine learning algorithms applied to predict pathology development in patients 
include one study19, which created a 16 variable Random Forest model with both clinical unstructured and struc-
tured data to predict hand, foot and mouth disease (HFMD). This approach improved the current clinical scoring 
system (AUC: 0.91) and is now being applied in practice. Furthermore, a similar approach to the one proposed 
here has been developed for early detection of pre-eclampsia involving the analysis of small non-coding RNAs 
(ncRNAs), with an AUC value of 0.86 generated after feature selection20. For other examples of dysregulated 
immune responses, namely sepsis21 and septic shock22 approaches that utilised data resulting from biomarker 
studies and routinely collected data held in electronic medical records yielded AUC values of 0.75 and 0.83 
respectively. Moreover, three blood protein biomarkers found through various machine learning approaches have 
been used in the diagnosis of mild traumatic brain injury (mTBI)23. Although genomic information has shown 
an incredible predictive performance for patient outcomes5, due to the long assay time and cost, genomics is not 
practical in the trauma setting. We have thus decided to complement previous work by applying our framework 
to recently published transcriptomic data acquired at similar time frames, namely within 2 hours of injury, in 
major trauma patients6.
Here, we aimed to assess the predictive value of early immunological events after trauma (<1 h, 4–12 h, 
48–72 h) as a diagnostic tool for MODS development. To do so, we have developed a framework consisting of 
both feature selection and performance evaluation. The selected features that will come out from the pipeline can 
be assessed as candidate biomarkers for the condition.
Results
The immune and inflammatory response to trauma was analysed in 89 adult trauma patients (mean age 41 
years, with an interquartile range (IQ) of 18-35-90 with 75 (84.3%) males) at three different time points (<1 h, 
4–12 h, 48–72 h)9. From these 89 patients, 61 were selected for a more thorough analysis given their complete 
datasets and availability of main outcome scoring assessments. Patient’s NISS score has a mean of 37.2 with an 
IQ range of 9-34-75 and the Population Survival (PS14) value has a mean of 81.73 with an IQ range of 19.21-
95.20-99.85. All the data sets contain information related to both immunological and clinical parameters with 
the immunological variables belonging to the following categories: neutrophil functional analysis (response to 
formyl-methionine-leucine-phenylalanine (fMLF)), monocyte response to lipopolysaccharides (LPS) stimula-
tion, haematological, cfDNA analysis and serum analysis (cytokines and cortisol). A more detailed description of 
all the parameters analysed can be found in the paper by Hazeldine et al.9 and in Supplementary Fig. 1.
For each of the study time points, two feature selection algorithms for MODS development, namely Least 
Absolute Shrinkage and Selection Operator (LASSO) and Elastic Net (EN) were applied. The performance of the 
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chosen features was then analysed through multivariate, and univariate machine learning models, with general-
ized linear models (GLM) having the best performance. Due to the high correlation between NISS and PS14 and 
the fact that they aggregate complex information such as gravity of the wound to estimate the extent of trauma 
damage, they are the predominant selected features at all time points, therefore analysis was performed in each 
time point separately (Fig. 1) to uncover the other important features.
Predictive model of MODS development. We repeated the analysis using data integrated from the three 
different time points and applied a more stringent threshold for feature selection. The final selected features were 
not significantly correlated and showed both biological significance and clinical relevance given the low cost and 
short time taken to perform their analysis (Fig. 2). By selecting the features irrespective of time points, we are 
selecting the overall highest associated changes with MODS development. With this approach, a further under-
standing of how the response develops might be reflected in this combination of time points, with multifaceted 
relations between components and kinetics revealed.
This multivariate combination of the third time point neutrophil decrease in CD62L expression after fMLF 
treatment and CD63 expression and monocyte frequency from the first time point resulted in the best performing 
models. By themselves, an AUC value of 0.874 ± 0.064 was achieved. The prediction ability of the model was then 
further improved with the addition of NISS and PS14 clinical scores, where AUC values of 0.917 ± 0.064 AUC 
and 0.922 ± 0.054 were obtained respectively. All three models, as seen in Fig. 2, were statistically significant 
with respect to pure randomness as exemplified by permuted data. By comparing with their univariate model 
performance, we can further establish a 13 and 8% increase in the predictive capability of NISS and PS14 scores, 
an improvement which, although not statistically significant, is of clinical importance (Supplementary Fig. 2).
Transcriptomics data analysis. In addition to the inflammatory markers, we used transcriptomics data 
obtained from the previous publication by Cabrera et al.6 and applied our feature selection framework to these 
data. The phenotypic information associated with this dataset, collected at similar ultra-early post-trauma time 
intervals, is consistent with the phenotypic information in our datasets. Crucially, traumatic brain injury patients 
Fig. 1 Univariate and multivariate performance (AUC values) of the selected features for the three different 
time points with PS14 (left) and NISS (right). The AUC performance values for each time point (a) <1 h,  
(b) 4–12 h, (c) 48–72 h are a result of 1000 GLM models of both permuted (yellow) and normal/real data (blue). 
On the left hand side of each figure a dumbell plot for each of the selected features per time point and the 
combination of all under “Multivariate” is presented. For each of these features, a univariate GLM model was 
built, with the average AUC values plotted. Here we present the selected features for each time point, and so 
those that correspond to the first quantile of frequencies of the 100 sparse models created in the LASSO and EN 
feature selection models (Methods: Fig. 5). On the right hand side, a density plot of the AUC values of the 1000 
permuted and non permuted GLM models of the selected features per time point is depicted. The average AUC 
value is presented in bold.
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were not included in either study or patients that received blood products prior to hospital admission. From the 
29,385 genes analysed, AMD1, C3AR1, FLI1, GIMAP4, GPI, GPR84, HLA-A29.1, LOC643373, MYLIP, VAT1, 
MANBA, SRXN1 were selected based on our feature selection algorithms with respect to MODS vs non-MODS 
classification prediction. A Gene Ontology Enrichment Analysis24,25 was performed on the selected genes, with 
the enriched biological pathways being myeloid leukocyte mediated immunity, neutrophil activation and neu-
trophil degranulation. A p-value of 2.8288e−5 was obtained for the neutrophil degranulation pathway associated 
with the VAT1, GPI, C3AR1, GPR84 and MANBA genes. More information on the chosen gene’s distribution can 
be found in Supplementary Fig. 3.
Fig. 2 Univariate and multivariate performance (AUC values) of the selected features for the integrated 
time points. (a) Univariate GLM AUC performance values of the selected features for the integrated data 
set containing features at all time points. (a) Density plot of the AUC values of the 1000 permuted and non-
permuted GLM models of the selected features together is depicted. (b) Density plot of the AUC values of the 
1000 permuted and non-permuted GLM models of the selected features plus PS14. (c) Density plot of the AUC 
values of the 1000 permuted and non-permuted GLM models of the selected features plus NISS. A confidence 
interval and p-value information of the multivariate model is also included in all figures. P-value was evaluated 
by assessing how many times a permuted value’s AUC was above the non-permuted/real AUC mean.
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Discussion
MODS is a complex multifactorial syndrome which develops in 30–40% of trauma patients3. In this study, we 
aimed to improve our understanding of its biological underpinnings through the analysis of the most relevant 
immunological markers at an ultra-early time point after injury and their changing dynamics at different time 
periods. In this way we have created a framework that allows the analysis of biologically relevant features so as to 
inform a more effective and timely medical intervention as well as patient stratification for therapy or inclusion in 
clinical trials. To do so, we have assessed the predictive power of early immunological and clinical data for MODS 
development after injury. As a result, a combination of four features have been determined as relevant clinical 
biomarkers, with a classification performance of 0.92 AUC value. All four features can be measured through 
inexpensive and technically feasible assays.
In this study, we performed validation in two ways, one is based on computational or in silico validation and 
the other is based on clinical or expert knowledge. In the computational framework we included double cross val-
idation as recommended in the literature to limit possible false positives and overfitting during training26–28. First, 
for feature selection, we performed a random split of the samples with 75% being training and 25% test. Further, 
we optimised our parameters on the 75% of the training samples by applying cross validation.
Feature selection was performed through two regularization methods: LASSO and EN. These methods were 
selected as they generate sparse models with ranking and selection of features, with easily interpretable frame-
works and results (linear models) suitable for the clinical data being analysed29. During performance assessment 
and after a 65% training and 35% testing split of the data, a model averaging was done to estimate the error rate 
on multiple iterations for an unbiased estimate to investigate the stability of the potential markers. In the liter-
ature recent studies have emphasized this aspect of using double cross validation to overcome the overfitting of 
–omics data sets. For example Acharjee et al. used a similar strategy on a metabolomics data set26, Filzmoser et al. 
applied this on near infrared (NIR) data27, Christin et al. performed it on proteomics and metabolomics data 
sets28. Regarding clinical validation, we included immunologists and clinicians’ expert opinions to the biomarkers 
chosen in addition to the literature based evidence.
Hazeldine et al.9 reported that “the complex nature of the acute immune response to injury suggests that 
targeting one element of the immune response is unlikely to reduce immune paresis or the incidence of MODS”. 
Understanding and predicting MODS development thus necessitates use of a multivariate approach that is 
able to reproduce heterogeneous and complex interactions. Other recent scoring systems such as A Severity 
Characterization Of Trauma (ASCOT) combine physiological parameters such as age and systolic blood pres-
sure30, and clearly demonstrate the value of physiological assessment. With the use of the current anatomically 
based scoring system (NISS) alone, a good MODS development predictive model can be developed with an AUC 
value of 0.72 (Figs. 1 and 2). But with the inclusion of data related to underlying immunological processes, an 
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Fig. 3 Visualisation of the non-normalized data distribution of the selected features after all time points  
data integration. (a) Decrease in neutrophil CD62L (L-selectin) after stimulation with fMLF (48–72 h).  
(b) Neutrophil CD63 expression (48–72 h) and (c). (a) Monocyte percentage plots for all patients (<1 h). Right: 
Violin-boxplot exhibiting change of marker through time for MODS and non-MODS patients. Left: Boxplot 
with p-value comparison following unpaired t-test between time points (<1 h, 4–12 h, 48–72 h).
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improvement of 13% with respect to NISS alone was achieved. Whilst NISS plays a vital role in the performance 
of a MODS prediction model (Supplementary Fig. 2), the discovery of relevant biological descriptors offers the 
possibility of potentially identifying clinical targets that may be used for intervention. For the future, we hope to 
find a marker or aggregation of markers able to substitute the complex anatomical information reflected in NISS 
and PS14 scores and so yield an objective and real time predictive parameter31,32. cfDNA and HMGB1 have been 
proposed as plausible substitutes18, though they were not selected here as the main features at any time point due 
to missing data. Moreover although our objective was to obtain a real time predictive parameter (i.e under 1 hour 
and easily available to clinicians), the features selected still allow for a prompt assay in a routine clinical lab and 
prediction of the patients outcome, given that MODS is assigned to those patients with a SOFA score of 6 or more 
in 2 consecutive days at least 48 hours post admission. Therefore, the earliest day MODS could be diagnosed 
would be day 4 post injury, with our algorithm able to predict this outcome at least 12 h before.
In order to further validate our results and create a generalizable model, more samples and of various origins 
are required. For example, since the same number of samples is required at each time point, studies similar in 
nature to ours, are likely to suffer from the fact that later time points are more likely to yield less samples (due 
to patient discharge or death etc). Therefore, the need for imputing data related to measurements from samples 
collected at later time points is especially high and hence the model’s prediction outcome should be critically 
evaluated and considered. Moreover, in our study, women were under represented (16% of patients being female). 
Therefore, sex differences were not corrected for which could have yielded different outcomes12. Moreover, extra 
features could be of interest too, such as information on the adaptive immune cell frequency or function or 
metabolite levels33. For example, albumin and lactate are two biomarkers of special interest given that they have 
been identified as having a significant correlation with the development of early MODS34–36. However, measure-
ments of albumin were not obtained in our study and lactate has not been identified as a key predictor of MODS 
in our studies. The latter could be attributed to the small number of patient samples that lactate measurements 
were available for, with the data shown in Supplementary Fig. 4.
All three features selected by our approach concern neutrophil function or frequency changes (Fig. 3). This is 
unsurprising as it is well understood that traumatic injury leads to marked alterations in the phenotype, function 
and life-span of circulating neutrophils with significant changes in the composition of the circulating neutrophil 
pool5. L-selectin (CD62L) is a receptor that facilitates tethering of neutrophils to the endothelium in inflamma-
tion and it has been shown to be significantly reduced on circulating neutrophils following severe trauma37,38. 
In our study, the bacterial tripeptide fMLF was used as a neutrophil stimulator ex vivo. Upon exposure to fMLF 
neutrophils would normally shed CD62L from their cell surface39, with increased levels of its soluble form present 
in the plasma as a result. In this study, shedding was less prominent in MODS patients than in non-MODs at all 
time points (Fig. 3a) suggesting a level of immunoparesis. A similar phenomenon has been previously reported in 
other receptors such as fMLF-induced expression of FcγRII (CD32)40. Reduced expression of CD63, a marker of 
primary granule exocytosis on the surface of neutrophils, is a well known marker for neutrophil activation. Primary 
granules or azurophils contain proteolytic enzymes such as elastase, a chief contributor to tissue damage in trauma 
patients41. Significantly, at time point three (48 to72h), patients who developed MODS had lower CD63 expression 
on their neutrophils when compared to patients who did not develop MODS (Fig. 3b). We hypothesize that this 
apparently less active peripheral pool of neutrophils in patients who have a worse outcome is due to those activated 
CD63 expressing neutrophils migrating into tissues/organs where they would cause damage and potentially con-
tribute to the pathogenesis of MODS. Finally, it is likely that the significantly lower monocyte percentage associated 
with the development of MODS in the first time point (<1 h) (Fig. 3c) is simply a consequence of the higher fre-
quency of neutrophils and immature granulocytes. In particular, medium-chain fatty acid receptor GPR84 and ves-
icle amine transport protein-1 (VAT-1), are both relevant to neutrophil function and the inflammatory response by 
regulating the oxidative burst42 and the response to fMLF respectively43. This is of interest given the tight relation-
ship with the CD62L response to fMLF in our models for MODS development and this requires further follow up.
The transcriptomics data were used as a means of complementing our immunological results and so provide 
a more insightful biological understanding of the early trauma response. As explained above, finding data com-
parable to our experimental design is difficult given its novelty but the transcriptomics data from Cabrera et al., 
2017 allowed integration given similar sampling times (<2 h, 24 h, 72 h and <1 h, 4–12 h, 48–72 h), and the use of 
MODs as an outcome variable (with similar criteria). We envisage the merging of different data types (immune 
and transcriptomics) will allow us to better understand MODS in our analysis. Support for this comes from our 
gene enrichment analysis where neutrophil activation and degranulation came out as important in the transcrip-
tomic data, in concordance with the immune markers associated with neutrophils that we found in our immune 
phenotype data.
To conclude, we present here a generalizable and automated framework that allows a reliable model with the 
yielding of a promising and encouraging preliminary result in MODS development prediction however, as a fol-
low up study an independent validation cohort is required. Our approach not only improves the performance of 
the current clinical scoring systems PS14 by 8% and NISS by 13% but, and perhaps more crucially, unveils possi-
ble biomarkers and mechanistic understanding of use for future prophylactic treatments for MODS.
Methods
Datasets. Data was obtained from 89 adult trauma patients (ISS ≥ 8) enrolled into the Brain Biomarkers 
After Trauma Cohort Study (NRES 13/WA/0399), a prospective observational study undertaken at the Queen 
Elizabeth Hospital Birmingham, UK. The development of MODS, defined by a Sequential Organ Failure 
Assessment (SOFA) score of 6 or more, on two or more consecutive days, at least 48 hours post-admission was 
the primary outcome of interest9. Development of MODS acted as the label for our binary classification mod-
els, where a score of 1 or 0 was assigned to patients who did or did not develop MODS respectively. The blood 
samples were acquired within 1 hour of injury (mean time to sample 42 minutes), 4–12 and 48–72 h post injury. 
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The Probability of Survival (PS14) was calculated by trained staff from the Trauma and Audit Research Network 
(TARN). It was modelled based on age, gender, Injury Severity Score (ISS), pre-existing medical conditions via 
the Charlson Comorbidity index (CCI), patient outcome (up to 30 days) and Glasgow Coma Score (GCS). If GCS 
was missing, intubation was used instead16. Further information regarding patient selection, consent and blood 
sampling has been described elsewhere9.
The transcriptomics data was publicly available from github/C4TS/HyperacutePhase6, with raw and normal-
ised gene expression values available under E-MTAB-5882. We obtained and applied our feature selection algo-
rithm to the normalised data using MODS vs nonMODS as label. The normalised data, contained gene expression 
values for 22,895 genes from samples obtained at different time points (<2 h, 24 h and 48 h) from 36 patients. Out 
of the 36 patients, 16 developed MODS and 20 did not. In this case, MODS was defined through a sequential 
organ failure assessment (SOFA) score of ≥5 (Golden Hour project establishes ≥6) on 2 or more consecutive 
days, excluding the first 48 hours. Moreover, these patients had blunt trauma and an ISS score above or equal to 25, 
with no traumatic brain injury. Further details about the normalisation procedure can be found in Cabrera et al.6.
Data pre-processing. Our data pre-processing approach, essential to obtain meaningful information from 
down-stream statistical analysis, involved four different stages, namely data cleaning and organising, distribution 
of data analysis visualization, missing data imputation and treatment of outliers, and normalisation. We treated 
missing values (NAs) in the following manner: Data with more than 70% missing values was eliminated and the 
remaining data were imputed where necessary. Imputations were introduced as the minimum value found per 
feature, after which, the datasets corresponding to the three different time points were autoscaled (standardised) 
using the scale function available within the norm R package. Patients that were able to be followed up for the 
three time points only were included, yielding three matrices of 61 patients and 68 features for time points one 
and two and 61 patients and 67 features for time point 3. A diagram of the steps followed is shown in Fig. 4, with 
more information about the selected features in Supplementary Fig. 1. For extra analysis, all three matrices were 
then blended into one big data matrix of 61 patients and 197 features. We have made all the code available in our 
GitHub repository github/InFlamUOB/NSDTraumaMODS.
Statistical and machine learning algorithms. Feature reduction was performed via applying two fea-
ture selection methods, Least Absolute Shrinkage and Selection Operator (LASSO) (1996)44 and Elastic Net 
(2005)45, two forms of regularization able to automatically select significant variables by shrinking the coefficients 
of unimportant predictors to zero (sparse representation). Our pipeline29 is composed of a variety of statistical 
machine learning modules described below.
Feature selection module. In order to apply the LASSO and EN algorithms for biologically relevant feature 
selection, we optimised the penalty parameter associated with each of the methods in an unbiased manner. To 
achieve this, the pipeline divided the samples randomly into a training set composed of 75% of the total num-
ber of the samples and a test set consisting of the remaining 25% samples. A 10-fold cross validation was then 
Fig. 4 Framework and pipeline of work. Four different data sets were run through the pipeline created 
consisting of feature selection and machine learning performance evaluation for best predictor of multiorgan 
dysfunction. These four datasets had the same patients studied in a longitudinal fashion with assessment of the 
three different time points and their combination.
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applied on the training set (inner loop set) aiming to have an optimised penalty parameter that can be used in the 
LASSO and EN models. Mathematically, LASSO and EN models can be defined by using a single penalty function 
“α”29,44,45 (Eq. 1).
β
β α β α β
∈
− − +
minimize
R
y X subject1
2
(1 )
(1)p 2
2
1
2
For example, for a penalty parameter α = 1, the LASSO algorithm is applied, whereas for α = 0.5 Elastic Net 
is performed. A high-value penalty parameter allows for a more stringent selection algorithm, with more β coef-
ficients reduced to 0. At α= 0, no feature selection is performed. These algorithms are implemented through the 
glmnet, ROC and caret packages.
Identification of candidate biomarkers. Our pipeline iterated the model creation process 100 times and 
features that appeared more frequently than a threshold number of times (the first upper quantile) were selected 
(Fig. 5), as these are deemed to be the more significant for the classification model. Moreover, in order to better 
understand the relationship between the features selected and the outcome variable analysed, weight’s (β coeffi-
cients) distribution per model was displayed and a boxplot of the class differences per feature generated. These 
selected features are then considered as potential candidate biomarkers. In order to ascertain their validity as 
biomarkers, their performance is evaluated both alone and in combination.
Performance evaluation and visualization. In order to assess the performance of the selected markers, 
our pipeline includes a stability analysis performed via a permutation test. This includes the randomization of the 
label features, resulting in incorrect sample labels for predictions and generating models with ROC AUC values 
showing a performance subject to the random distribution. A generalized linear model (GLM) was applied on 
1000 random samplings of 65% training and 35% test sets in both real data (correct simple label) and permuted 
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Fig. 5 Feature selection and beta coefficients for both LASSO and EN algorithms for the first time point with 
NISS. (a) A graphical representation representing the frequency of feature appearance in the 100 models run 
for LASSO. Those features that appear in more than the threshold (above dotted line) are then selected. (b) A 
representation of the 100 beta coefficients found for each of the 100 models of the features selected by both 
algorithms (LASSO in blue and EN in orange).
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ones. ROC AUC performance results were computed for each of these models and plotted as density plots along-
side their means (Figs. 1 and 2). The ROC AUC offers a graphical overview of the diagnostic ability of binary 
classifiers with varying thresholds.
Software and data repositories. This pipeline was executed with four different datasets as seen in Fig. 4. 
At each time point the most important features were selected. A final data matrix, created through the combina-
tion of all the previous matrices together, was used to identify the most relevant features for MODS classification 
for the early immunological response (<1 h to 72 h). All analyses were performed in the R statistical computing 
(R version 3.5.2) environment. All R packages can be obtained from our project’s github repository. The necessary 
software dependencies are described in the README file located in the repository. All analyses can be performed 
on a standard PC environment with the run time increasing with larger datasets. Code is compiled and figures 
and key data such as selected features stored automatically for accessible future use as explained in the README 
file associated. Plots were generated with geom_dumbell and ggplot2 functions.
Gene ontology (GO) enrichment analysis. Enrichment analysis were performed through both Enrichr24 
and Reactome25 platforms after multiple test correction.
Data availability
The complete 89 patient dataset can be found in Hazeldine et al.9 and the 61 patient dataset at the three time points 
with which we have generated all results is available in our github repository InFlamUOB/NSDTraumaMODS46 
and figshare47. All of the figures, including supplementary, have also been added to figshare (https://doi.
org/10.6084/m9.figshare.10322099).
Code availability
The scripts used for all data analyses, implemented in R are available in the github repository github/InFlamUOB/
NSDTraumaMODS46 and accessible through figshare too48.
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